Sign in to view content

MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes From the Phase 2 STARLIGHT Trial

Allen C Ho, MD FASRS

Video
Published 2023

Related

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Suprachoroidally delivered gene therapy via non-viral DNA nanoparticles
Christine Kay, MD
On Demand Cases, Courses, and Papers
2019
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021

Category: Hereditary Retinal Disease & Genetics

See more